Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: Intergroup trial of the AGO-Ovar/AIO and EBMT

Journal of Clinical Oncology

Volumn 25, Issue 27, 2007, Pages 4187-4193

  Möbus, Volker ^a   Wandt, Hannes ^b   Frickhofen, Norbert ^b   Bengala, Carmelo ^b   Champion, Kim ^b   Kimmig, Rainer ^b   Ostermann, Helmut ^b   Hinke, Axel ^b   Ledermann, Jonathan A ^b  

^a Eye Hospital   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; MELPHALAN; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TOPOTECAN; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DIARRHEA; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG MEGADOSE; DYSPNEA; ESOPHAGITIS; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HAZARD RATIO; HEART ARRHYTHMIA; HEMORRHAGIC SHOCK; HUMAN; INFECTION; LEUKAPHERESIS; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; OTOTOXICITY; OUTCOME ASSESSMENT; OVARY CANCER; PATIENT COMPLIANCE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; RANDOMIZATION; STANDARD; STOMATITIS; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; OVARY TUMOR; PATHOLOGY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; STEM CELL TRANSPLANTATION; TIME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MELPHALAN; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; STEM CELL TRANSPLANTATION; TIME FACTORS; TREATMENT OUTCOME;

EID: 34948897497     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.09.7527     Document Type: Article

References (34)

1. Ozols RF, Bundy BN, Greer BE, et al: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 21:3194-3200, 2003
2. du Bois A, Lueck HJ, Meier W, et al: A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95:1320-1329, 2003
3. Neijt JP, Engelholm SA, Tuxen MK, et al: Exploratory phase III Study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 18:3084-3092, 2000
4. Kaye SB, Paul J, Cassidy J, et al: Mature results of a randomized trial of two doses of cisplatin for thetreatment of ovarian cancer: Scottish Gynecology Cancer Trials Group. J Clin Oncol 14:2113-2119, 1996
5. Hogberg T, Glimelius B, Nygren P: A systematic overview of chemotherapy effects in ovarian cancer. Acta Oncol 40:340-360, 2001
6. Alberts DS, Liu PY, Hannigan EV, et al: Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335:1950-1955, 1996
7. Markman M, Bundy BN, Alberts DS, et al: Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group J Clin Oncol 19:1001-1007, 2001
8. Armstrong DK, Bundy B, Wenzel L, et al: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34-43, 2006
9. Stiff PJ, Veum-Stone J, Lazarus HM, et al: High-dose chemotherapy and autologous stem-cell transplantation for ovarian cancer: An Autologous Blood and Marrow Transplant Registry report. Ann Intern Med 133:504-515, 2000
10. Ledermann JA, Herd R, Maraninchi D, et al: High-dose chemotherapy for ovarian carcinoma: Long-term results from the Solid Tumor Registry of the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol 12:693-699, 2001
11. Donato ML, Aleman A, Champlin RE, et al: Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation. Bone Marrow Transplant 33:1219-1224, 2004
12. Legros M, Dauplat J, Fleury J, et al: High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: Long-term results. J Clin Oncol 15:1302-1308, 1997
13. Aghajanian C, Fennelly D, Shapiro F, et al: Phase II study of "dose-dense" high-dose chemotherapy treatment with peripheral-blood progenitor-cell support as primary treatment for patients with advanced ovarian cancer J Clin Oncol 16:1852-1860, 1998
14. Fenelly D, Schneider J, Spriggs D, et al: Dose escalation of paclitaxel with high-dose cyclophosphamide, with analysis of progenitor-cell mobilization and hematologic support of advanced ovarian cancer patients receiving rapidly sequenced high-dose carboplatin/cyclophosphamide courses. J Clin Oncol 13:1160-1166, 1995
15. Wandt H, Birkmann J, Denzel T, et al: Sequential cycles of high-dose chemotherapy with dose escalation of carboplatin with or without paclitaxel supported by G-CSF mobilized peripheral blood progenitor cells: A phase I/II study in advanced ovarian cancer. Bone Marrow Transplant 23:763-770, 1999
16. Frickhofen N, Berdel WE, Opri F, Haas R, et al: Phase I/II trial of multicycle high dose chemotherapy with peripheral blood stem cell support for treatment of advanced ovarian cancer. Bone Marrow Transpl 38:493-499, 2006
17. Calvert AH, Newell DR, Gumbrell LA, et al: Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748-1756, 1989
18. Jelliffe RW: Creatinine clearance: Bedside estimate. Ann Intern Med 79:604-605, 1973
19. Lan KKG, DeMets DL: Discrete sequential boundaries for group sequential trials. Biometrika 70:659-663, 1983
20. O'Brien PC, Fleming TR: A multiple testing procedure for clinical trials. Biometrics 35:549-555, 1979
21. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6, 1996
22. Piccart MJ, Bertelsen K, James K, et al: Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three year results. J Natl Cancer Inst 95:699-708, 2000
23. du Bois A, Quinn M, Thigpen T, et al: 2004 consensus statement on the management of ovarian cancer: Final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 16:viii7-viii12, 2005 (suppl 8)
24. du Bois A, Weber B, Rochon J, et al: Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: A prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. J Clin Oncol 24:1127-1135, 2006
25. Pfisterer J, Weber B, Reuß A, et al: Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: A gynecologic cancer intergroup trial of the AGO-Ovar and GINECO. J Natl Cancer Inst 98:1036-1045, 2006
26. De Placido S, Scambia G, Di Vagno G, et al: Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian trials in ovarian cancer (MITO-1) randomized study. J Clin Oncol 22:2635-2642, 2004
27. Bookman MA, for the Gynecologic Cancer InterGroup (GCIG) through the Gynecologic Oncology Group (GOG): GOGO 182-ICON5: 5-arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG-lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma. J Clin Oncol 24:256s, 2006 (suppl; abstr 5002)
28. McGuire WP, Hoskins WJ, Brady MF, et al: Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 13:1589-1599, 1995
29. Stiff P, Bayer R, Camarda M, et al: A phase H trial of high-dose mitoxantrone, carboplatin, and cyclophosphamide with autologous bone marrow rescue for recurrent epithelial ovarian carcinoma: Analysis of risk factors for clinical outcome. Gyn Oncol 57:278-285, 1995
30. Curé H, Legros M, Fleury J et al: High-dose chemotherapy and autologous stem cell transplantation in advanced epithelial ovarian cancer. Bone Marrow Transpl 18:34-35, 1996 (suppl 1)
31. Curé H, Battista C, Guastalla JP et al: Phase III randomized trial of high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) support as consolidation in patients (pts) with advanced ovarian cancer (AOC): 5-year follow-up of a GINECO/FNCLCC/SFGM-TC study. J Clin Oncol 23:450s, 2004 (abstr 5006)
32. Grénman S, Wiklund T, Jalkanen J, et al: A randomised phase III study comparing high-dose chemotherapy to conventionally dosed chemotherapy for stage III ovarian cancer: The Finish Ovarian cancer (FINOVA) study. Eur J Cancer 42:2196-2199, 2006
33. Gonçalves A, Delva R, Fabbro M, et al: Post-operative sequential high-dose chemotherapy with haematopoietic stem cell support as front-line treatment in advanced ovarian cancer: A phase II multicentre study. Bone Marrow Transplant 37:651-659, 2006
34. Schilder RJ, Brady MF, Spriggs D, et al: Pilot evaluation of high-dose carboplatin and paclitaxel followed by high-dose melphalan supported by peripheral blood stem cells in previously untreated advanced ovarian cancer: A Gynecologic Oncology Group study. Gynecol Oncol 88:3-8, 2003